KRAS and familial pancreatic carcinoma: In conclusion, at a detection limit of 0.08% allelic fraction, our amplicon-based KRAS mutations sequencing assay applied to a large case-control series of plasma samples showed a limited sensitivity of 21.1% for the detection of pancreatic cancer and was not as specific as anticipated.